Efficacy of edaravone, a free radical scavenger, for the treatment of acute lacunar infarction.
The effect of edaravone as an inhibitor of ischemic brain damage in addition to routine treatment was retrospectively examined in 70 patients with lacunar infarction who were admitted within 24 hours of symptom onset. Clinical status was assessed using the National Institutes of Health Stroke Scale (NIHSS). The modified Rankin Scale (MRS) was used to assess clinical outcomes at 3 months after onset, with a good outcome defined as MRS score < or =2. Risk factors were also evaluated, including evidence of hypertension, diabetes mellitus, hyperlipidemia, coronary heart disease, and a history of smoking longer than 2 months. The probability of a good outcome and independence at 3 months was assessed by backward stepwise logistic regression analysis based on the maximum likelihood ratio. Administration of edaravone yielded an odds ratio with multivariate adjustment of 6.49 (95% confidence interval, 1.35 to 50.32; p < 0.05) for a good outcome at 3 months. Higher baseline NIHSS score and higher age also adversely affected the outcome at 3 months (p < 0.005). Administration of edaravone improves the outcome of patients with lacunar infarction.
Mishina
Masahiro
M
The Department of Neurology, Neurological Institute, Nippon Medical School Chiba-Hokusoh Hospital.
Komaba
Yuichi
Y
Kobayashi
Shiro
S
Tanaka
Nobuyuki
N
Kominami
Shushi
S
Fukuchi
Takaharu
T
Mizunari
Takayuki
T
Hamamoto
Makoto
M
Teramoto
Akira
A
Katayama
Yasuo
Y
D000208:Acute Disease; D000368:Aged; D000983:Antipyrine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D020520:Brain Infarction / Q000188:drug therapy* / Q000503:physiopathology; D000077553:Edaravone; D005260:Female; D016166:Free Radical Scavengers / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D012189:Retrospective Studies; D016896:Treatment Outcome
D016166:Free Radical Scavengers; D000077553:Edaravone; D000983:Antipyrine